<?xml version="1.0" encoding="UTF-8"?>
<p>In the last decade, alternatives to ACV for herpesvirus treatment have emerged and become commercially available as therapeutic drugs. Ganciclovir is a nucleic acid analog that does not require viral proteins for its activation in the cell (i.e., viral TK) (
 <xref rid="B122" ref-type="bibr">Markham and Faulds, 1994</xref>; 
 <xref rid="B149" ref-type="bibr">Prichard et al., 2011</xref>; 
 <xref rid="B194" ref-type="bibr">Vere Hodge and Field, 2013</xref>; 
 <xref rid="B146" ref-type="bibr">Poole and James, 2018</xref>). These compounds differ from each other either, in their molecular processing into an active form of an acyclic guanosine analog, or bioavailability which significantly determines the frequency of administration (
 <xref rid="B42" ref-type="bibr">De Clercq, 2013</xref>).
</p>
